I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript August 17, 2023 8:00 AM ET
Company Participants
Tyler Ehler - Senior Director for IR
Raj Kannan - CEO
John Hayslip - CMO
Richard Yeh - Interim CFO and COO
Andrew Zhu - President and Head of R&D
Conference Call Participants
Kelly Shi - Jefferies
Joe Catanzaro - Piper Sandler
Louise Chen - Cantor Fitzgerald
Gil Blum - Needham & Company
Andres Maldonado - H.C. Wainwright
Xiaoyi Qu - CICC
Bing Zhao - China Renaissance
Zhuxuan Jiang - CITIC Securities
Tyler Ehler
Good morning, everyone, and thank you for joining us this morning and for standing by. I'd like to take this opportunity to welcome you all to the I-Mab Biopharma Mid-Year 2023 Financial Results and Business Update Conference Call. My name is Tyler Ehler, and I'm I-Mab's Senior Director for Investor Relations. At this time, all participants are in a listen-only mode. At end of this call, we will conduct a Q&A session and instructions will follow at that time.
Earlier today, we issued a press release providing a review of our financial results for the mid-year ended June 30, 2023, as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the Investor Relations tab on our website at ir.i-mabbiopharma.com.
Joining me today on the call from I-Mab’s senior management team are Raj Kannan, CEO; Dr. John Hayslip, Chief Medical Officer; Dr. Andrew Zhu, President and Head of R&D; and Richard Yeh, Interim CFO and COO. Raj will provide a high-level overview of our recent achievements and upcoming milestones, and John will provide an update on our R&D progress. Richard will then provide a summary of our financial results for the six months ended June 30, 2023, before we turn the call over to Raj for a few final comments. And then back to the operator to take your questions.
Please note that today's discussion will contain forward-looking statements relating to the company's future performance and the forward-looking statements are made under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions and other factors. Some of these risks are beyond the company's control and could cause actual results to differ materially from those mentioned in today's press release and on this earnings call. A general discussion of the risk factors that could affect I-Mab's business and financial results is included in certain filings of the company with the Securities and Exchange Commission, including, but not limited to, the Risk Factors section in I-Mab's most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties and other important factors in I-Mab's subsequent filings with the SEC.